Patent Boost for Heart Shunt System Amid FDA Review Delays
Published Date: 3/5/2026
Notice
Summary
The U.S. Patent Office just gave V-Wave Ltd. a one-year extra boost on their patent for the V-WAVE Ventura Interatrial Shunt System because the FDA review is still happening. This means V-Wave keeps exclusive rights to their medical device until March 11, 2027, giving them more time to market it without competition. It’s a win for innovation and business while the final FDA approval is still in progress!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
One-Year Patent Extension Granted
The U.S. Patent Office granted V-Wave Ltd. a one-year interim extension of U.S. Patent No. 9,724,499 for the V-WAVE Ventura Interatrial Shunt System. The patent’s original expiration date was March 11, 2026, and the extension keeps the patent in force from that date for one year (through March 11, 2027), giving V-Wave more time to market the device without competition.
Law Allows Multiple Interim Extensions
Under 35 U.S.C. 156(d)(5), a patent subject to regulatory review may receive up to five interim extensions of up to one year each if the approval phase of the regulatory review is reasonably expected to extend beyond the patent’s expiration. This notice represents a first interim extension under that provision.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in